2024-10-21
Participating in CPHI Worldwid
Release Time: 2024-09-23
News Source: PharmaCompass
Author: SENOVA—Lucas
Novo Nordisk has entered into an allinclusive US$ 530milion deal with Korro Bio to collaborate on two cardiometabolic-related targets. This partnership leverages Korro's Oligonucleotide Promoted Editing of RNA (OPERA) platform, which aims to "use an oligonucleotide to co-opt a natura process in the human body to make changes in mRNA encoding the protein, leaving the DNA genome unaltered." This approach could potentially address previously undruggable targets for cardiometabolic diseases, such as obesity,diabetes, and cardiovascular conditions.Meanwhile, Novo Nordisk expects its diabetes drug, Ozempic (semaglutide), to be included in the US government's 2027 list for Medicare price negotiations.
